骨髓增生异常综合征2011 NCCN诊疗指南解读

孙耘玉; 陈宝安; 丁家华; 高冲

doi:10.13201/j.issn.1004-2806.2012.02.007

骨髓增生异常综合征2011 NCCN诊疗指南解读

- 东南大学附属中大医院血液科(江苏省医学重点学科)/MDS研究所(南京, 210009)
基金项目:
江苏省医学重点学科资助

国家科技支撑计划课题(十一五)子课题(No:2008BAI61B02)

详细信息

通讯作者: 陈宝安,E-mail:cba8888@hotmail.com

中图分类号: R551.3

收稿日期: 2011-07-19

修回日期: 2012-01-18

Interpretation of the myelodysplastic syndrome 2011 NCCN diagnosis and treatment guidelines

- Department of Hematology, Zhongda Hospital, Southeast University, Nanjing, 210009, China

More Information

Corresponding author: CHEN Baoan, E-mail: cba8888@hotmail.com

Received Date: 19 July 2011

Revised Date: 18 January 2012

摘要

摘要: 目的:为国内骨髓增生异常综合征(MDS)规范诊断治疗提供参考。方法:对美国国家综合癌症网络(NCCN)2011年版MDS临床指南进行解读。从MDS的诊断分型、初始评估、预后分层及治疗选择方面进行全面阐述,以期对国内MDS的规范诊疗有所帮助。结果:NCCN MDS诊疗指南是基于对不同风险患者研究数据的广泛评价,代表了目前MDS诊断治疗的有效方法。结论:NCCN 2011版MDS诊疗指南可以为国内同行提供很好的借鉴。
- 骨髓增生异常综合征 /
- 诊断 /
- 治疗 /
- 临床指南
Abstract: Objective:To provide a reference of the diagnosis and treatment in MDS to domestic counterparts. Method:.Comprehensive explanation in diagnostic classification,initial evaluation,prognositic stratification,and therapeutic options were made to interpret the clinical guidelines of myelodysplastic syndrome 2011 NCCN.Result:NCCN MDS Practice Guidelines are based on different risk-assessment of patients with extensive research data.Represents the current effective method of diagnosis and treatment.Conclusion:NCCN 2011 MDS practice guideline can provide a good reference for the domestic counterparts.
- myelodysplastic syndrome /
- diagnosis /
- treatment /
- clinical guidelines

HTML全文

参考文献(24)

[1]	VARDIMAN J W,HARRIS N L,BRUNNING R D.The World Health Organization(WHO)classification of the myeloid neoplasmas[J].Blood,2002,100:2292-2302.
[2]	GREENBERG P,COX C,LEBEAU M M,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[J].Blood,1997,89:2079-2088.
[3]	VALENT P,HORNY H P,BENNETT J M,et al.Definitions and standars in the diagnosis and treatment of the myelodysplastic syndromes:Consensus statements and report from a working conference[J].Leuk Res,2007,31:727-736.
[4]	DUNN D E,TANAWATTANACHAROEN P,BOCCUNI P,et al.Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes[J].Ann Intern Med,1999,131:401-408.
[5]	SAUNTHARARAJAH Y,NAKAMURA R,NAM J M,et al.HLA-DR15(DR2)is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome[J].Blood,2002,100:1570-1574.
[6]	GREGG X T,REDDY V,PRCHAL J T.Copper deficiency masquerading as myelodysplastic syndrome[J].Blood,2002,100:1493-1495.
[7]	KOCA E,BUYUKASIK Y,CETINER D,et al.Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts[J].Leuk Res,2008,32:495-499.
[8]	SANZ G F,SANE M A,GREENBERG P L.Prognostic factors and scoring systems in myelodysplastic syndromes[J].Haematologica,1998,83:358-368.
[9]	CERMAK J,KACIRKOVA P,MIKULENKOVA D,et al.Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts[J].Leuk Res,2009,33:1469-1474.
[10]	PARK M J,KIM H J,KIM S H,et al.Is international Prognostic Scoring System(IPSS)still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System(WPSS)and comparision with IPSS[J].Eur J Haematol,2008,81:364-373.
[11]	MALCOVATI L.Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes[J].Leuk Res,2007,31 Suppl 3:2-6.
[12]	JENSEN P D,HEICKENDORFF L,PEDERSEN B,et al.The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload[J].Br J Haematol,1996,94:288-299.
[13]	FENAUX P,MUFTI G J,HELLSTROM-LINDBERG E,et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of high-risk myelodysplastic syndromes:a randomised,openlabel phase Ⅲ study[J].Lancet Oncol,2009,10:223-232.
[14]	KANTARJIAN H,ISSA J P,ROSENFELD C S,et al.Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase Ⅲ randomized study[J].Cancer,2006,106:1794-1803.
[15]	LIST A,KURTIN S,ROE D J,et al.Efficacy of lenalidomide in myelodysplastic syndromes[J].N Engl J Med,2005,352:549-557.
[16]	NIMER S D.Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q[J].J Clin Oncol,2006,24:2576-2582.
[17]	ESTEY E H,THALL P F,CORTES J E,et al.Comparison of idarubicin+ara-C,fludarabine+ara-C,and topotecan+ ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia,refractory anemia with excess blasts in transformation,or refractory anemia with excess blasts[J].Blood,2001,98:3575-3583.
[18]	SCOTT B L,SANDMAIER B M,STORER B,et al.Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineaga dysplasia:a retrospective analysis[J].Leukemia,2006,20:128-135.
[19]	ALYEA E P,KIM H T,HO V,et al.Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age[J].Blood,2005,105:1810-1814.
[20]	CUTLER C S,LEE S J,GREENBERG P,et al.A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:delayed transplantation for low-risk myelodysplassia is associated with improved outcome.Blood[J],2004,104:579-585.
[21]	BERAN M,SHEN Y,KANTARJIAN H,et al.High-dose chemotherapy in high-risk myelodysplastic syndrome:covariate-adjusted comparison of five regimens[J].Cancer,2001,92:1999-2015.
[22]	WIJERMANS P,SUCIU S,BAILA L,et al.Low dose decitabine versus best supportive care in elderly patients with intermediate or high-risk MDS not eligible for intensive chemotherapy:Final results of the randomized phase Ⅲ study(06011)of the EORTC leukemia and German MDS study groups[J].Blood,2008,112:226-226.
[23]	SPIRTI M A,LATAGLIATA R,NISCOLA P,et al.Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome[J].Ann Hematol,2005,84:167-176.
[24]	HELLSTROM-LINDBERG E,GULBRANDSEN N,LINBERG G,et al.A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor:significant effects on qulity of life[J].Br J Haematol,2003,120:1037-1046.